Member Info for John2015

which actually appears to have come to nothing as no seals have been reported,
How long does it take ? Lots of negative press about tests and the company makes no move to defend itself or rebuff the bad reports either by disputing them or advising better tests available.
Come on ODX do something, say something !

No news, no trades of any size, market opens and sp “drops” 1.50 ?
No it hasn't the bid is what it was the Ask is what it was MM's trying to use the spread to make it look like there is movement.
Roll on January 2nd and, maybe, some real news.

When nothing changed ?
Am I missing something or did somebody just get bored ?

How - or even if Aex funds itself.

Checked with local council - plans to go ahead with rapid testing for those without symptoms are being put in place and will be rolled out from mid January. Those with syptoms can get a rapid test on demand via the council website.
Looks to me as if both positions (tests available and tests postponed) are true. Those with symptoms can get a test, although it may be one of the less reliable ones. Those without will need to wait until 2nd half of January, when presumably the more accurate tests will be available ( consistent with Guardian report ).
It would be nice to have a comment (RNS) from the company.

Checked with local council - plans to go ahead with rapid testing for those without symptoms are being put in place and will be rolled out from mid January. Those with syptoms can get a rapid test on demand via the council website.
Looks to me as if both positions (tests available and tests postponed) are true. Those with symptoms can get a test, although it may be one of the less reliable ones. Those without will need to wait until 2nd half of January, when presumably the more accurate tests will be available ( consistent with Guardian report ).
It would be nice to have a comment (RNS) from the company.

I accept that some false negatives is not ideal - but if tests detect 70% of those with Coronavirus how is that worse than having no tests at all - while the government thinks about this for another month ( and 500 people a day succumb to the virus ) ?
Doing the tests ( while you improve the design and accuracy then upgrade them )must be a better way surely ?

I accept that some false negatives is not ideal - but if tests detect 70% of those with Coronavirus how is that worse than having no tests at all - while the government thinks about this for another month ( and 500 people a day succumb to the virus ) ?
Doing the tests ( while you improve the design and accuracy then upgrade them )must be a better way surely ?

Honest opinion no you are right - my mistake.
The prices paid are all over 1.25 so they seem to be buys at the price on Friday - so someone seems to be buying a lot of shares, but the price still fell today. Weird.

As the price was 1.25 it looks to me like these are placing shares bought in advance - and therefore conditional on the shareholder meeting ? As the sp has now been lowered by the dilution and placing price I can't see it going up until the 400m are bought.

You are right Crusty.

and still the sp falls along with almost every other covid stock except NCYT ?
Sometimes the markets defy all logic.
No doubt the shorters are having a field day (especially on the main markets) only to pump them up later this week/month.

( About another share ) "Watch these ba*tar*s - they'll steal your eyeballs and then come back to scrape your sockets".
Sadly it seems that Mr Cave has managed to get himself ( and us ) mixed up with a couple of characters who fit the profile remarkably well.
Hoping this company gets a chance to deliver what it could and should, despite their efforts.

Watch it close flat. - the MM's are taking the p*ss.
Mind you if the Ask goes down a bit more I might be tempted.

Done.

What does the MHRA do?

The MHRA is an executive department of the Department of Health and Social Care and is the body that regulates medicines, medical devices and blood components for transfusion in the UK.

Until the end of December, and as part of the transition period, COVID-19 vaccine candidates can be licensed via the European Medicines Agency (EMA) and that authorisation will automatically be valid in the UK.

If a suitable COVID-19 vaccine candidate – with strong supporting evidence of safety, quality and effectiveness from clinical trials – becomes available before the end of the transition period, EU legislation allows for temporary authorisation of supply in the UK, based on the public health need.

In the event of a temporary authorisation for supply, the MHRA will evaluate the data rigorously for quality, safety and effectiveness to reach an independent, scientifically robust opinion. The data must include, for example, results from lab and clinical trials in humans, manufacturing and quality controls, product sampling, and testing of the final product.

Once the MHRA has thoroughly reviewed the data, they will seek advice from the Government’s independent advisory body, the Commission on Human Medicines. The Commission will critically assess the data too before advising the UK government on the safety, quality and effectiveness of any potential vaccine.

Any COVID-19 vaccine candidate submitted after the transition period ends in January 2021 will not need to go through a European marketing authorisation for use in Great Britain and will instead be assessed directly by the MHRA.

The MHRA is globally recognised for requiring the highest standards of safety, quality and effectiveness for any vaccine.?It has responsibility in law to continuously evaluate all products on the UK market.

Following COVID-19 vaccine approval, the MHRA has in place a robust and proactive safety monitoring strategy which allows for near real-time safety monitoring at population level.

What does the MHRA do?

The MHRA is an executive department of the Department of Health and Social Care and is the body that regulates medicines, medical devices and blood components for transfusion in the UK.

Until the end of December, and as part of the transition period, COVID-19 vaccine candidates can be licensed via the European Medicines Agency (EMA) and that authorisation will automatically be valid in the UK.

If a suitable COVID-19 vaccine candidate – with strong supporting evidence of safety, quality and effectiveness from clinical trials – becomes available before the end of the transition period, EU legislation allows for temporary authorisation of supply in the UK, based on the public health need.

In the event of a temporary authorisation for supply, the MHRA will evaluate the data rigorously for quality, safety and effectiveness to reach an independent, scientifically robust opinion. The data must include, for example, results from lab and clinical trials in humans, manufacturing and quality controls, product sampling, and testing of the final product.

Once the MHRA has thoroughly reviewed the data, they will seek advice from the Government’s independent advisory body, the Commission on Human Medicines. The Commission will critically assess the data too before advising the UK government on the safety, quality and effectiveness of any potential vaccine.

Any COVID-19 vaccine candidate submitted after the transition period ends in January 2021 will not need to go through a European marketing authorisation for use in Great Britain and will instead be assessed directly by the MHRA.

The MHRA is globally recognised for requiring the highest standards of safety, quality and effectiveness for any vaccine.?It has responsibility in law to continuously evaluate all products on the UK market.

Following COVID-19 vaccine approval, the MHRA has in place a robust and proactive safety monitoring strategy which allows for near real-time safety monitoring at population level.

What does the MHRA do?

The MHRA is an executive department of the Department of Health and Social Care and is the body that regulates medicines, medical devices and blood components for transfusion in the UK.

Until the end of December, and as part of the transition period, COVID-19 vaccine candidates can be licensed via the European Medicines Agency (EMA) and that authorisation will automatically be valid in the UK.

If a suitable COVID-19 vaccine candidate – with strong supporting evidence of safety, quality and effectiveness from clinical trials – becomes available before the end of the transition period, EU legislation allows for temporary authorisation of supply in the UK, based on the public health need.

In the event of a temporary authorisation for supply, the MHRA will evaluate the data rigorously for quality, safety and effectiveness to reach an independent, scientifically robust opinion. The data must include, for example, results from lab and clinical trials in humans, manufacturing and quality controls, product sampling, and testing of the final product.

Once the MHRA has thoroughly reviewed the data, they will seek advice from the Government’s independent advisory body, the Commission on Human Medicines. The Commission will critically assess the data too before advising the UK government on the safety, quality and effectiveness of any potential vaccine.

Any COVID-19 vaccine candidate submitted after the transition period ends in January 2021 will not need to go through a European marketing authorisation for use in Great Britain and will instead be assessed directly by the MHRA.

The MHRA is globally recognised for requiring the highest standards of safety, quality and effectiveness for any vaccine.?It has responsibility in law to continuously evaluate all products on the UK market.

Following COVID-19 vaccine approval, the MHRA has in place a robust and proactive safety monitoring strategy which allows for near real-time safety monitoring at population level.

Kaylinblue in brief Seems to be a progress report. Click view in full tab. Summary below.
26226 UK 18/8/20 - 25/10/21 AGES 18-55 0NGOING PHASE11 DATA SUBMITTED ? PHASE 111 UP TO 10/21 NO RESULTS PUB.
26186 RUSSIA 02/09/20 - 12/03/21 AGES 18-130 SUSPENDED
26250 US & UK 2/12/20 - 04/01/22 AGES 18-120 ONGOING ( US REGULATOR REQUEST ? MY QUERY) NO RESULTS PUB.
26249 SPAIN, US, UK, EU 21/11/20 - 03/02/22 18+ NO MAX ONGOING NO RESULTS
26198 US & S.AMERICA 28/08/20 - 23/03/21 AGES 18 - 130 0NGOING PHASE11 DATA SUBMITTED ? PHASE 111 UP TO 03/21 NO REULTS PUB.
Basically a list of trials some Phase 2 info submitted - we're waiting on MHRA approval US want more trials (26250) before they will approve. All trials will go on to monitor vaccinees for 1 year or more but initial data has been submitted for 26226 & 26198 - We just need the MHRA to approve. No idea why its taking them so long Lancet says vaccine is safe and effective !

Very nice - but, an RNS on sales would be much nicer !